Lyles CM, Dorrucci M, Vlahov D.
et al. Longitudinal HIV-1 load in the Italian Seroconversion Study: correlates
and temporal trends of virus load. J Infect Dis.1999;180:1018-1024.
O'Brien TR, Rosenberg PS, Yellin F, Goedert JJ. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol.1998;18:155-161.
Hubert J-B, Burgard M, Dussaix E.
et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known
date of infection. AIDS.2000;14:123-131.
Sabin CA, Devereux H, Phillips AN, Janossy G, Lee CA, Loveday C. The course of viral load throughout HIV-1 infection. J Acquir Immune Defic Syndr.2000;23:172-177.
Lane HC, Masur H, Gelmann EP.
et al. Correlation between immunologic function and clinical subpopulations
of patients with the acquired immune deficiency syndrome. Am J Med.1985;78:417-422.
Phillips AN, Lee CA, Elford J, Janossy G, Kernoff PBA. The cumulative risk of AIDS as the CD4 lymphocyte count declines. J Acquir Immune Defic Syndr.1992;5:148-152.
Staszewski S, Miller V, Sabin CA.
et al. Determinants of sustainable CD4 lymphocyte count increases in response
to antiretroviral therapy. AIDS.1999;13:951-956.
Miller V, Staszewski S, Nisius G.
et al. Risk of new AIDS diseases in people on triple therapy. Lancet.1999;353:463.
Ledergerber B, Egger M, Opravil M.
et al. Clinical progression and virologic failure on highly active antiretroviral
therapy in HIV-1 patients: a prospective cohort study. Lancet.1999;353:863-868.
BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association Guidelines for the treatment of HIV infected
adults with antiretroviral therapy. HIV Med.2000;1:76-101.
Carpenter CCJ, Cooper DA, Fischl MA.
et al. Antiretroviral therapy in adults. Updated recommendations of the International
AIDS Society—USA Panel. JAMA.2000;283:381-390.
Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline
characteristics. Soz Praventivmed.1994;39:387-394.
Lundgren JD, Phillips AN, Vella S.
et al. Regional differences in use of antiretroviral agents and primary prophylaxis
in 3122 European HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol.1997;16:153-160.
Staszewski S, Miller V, Sabin CA.
et al. Virological response to protease inhibitor therapy in an HIV clinic
Shuurman R, Descamps D, Weverling GJ.
et al. Multicenter comparison of three commercial methods for quantification
of HIV-1 RNA in plasma. J Clin Microbiol.1996;34:3016-3022.
Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of
protease inhibitor-based regimens in patients with HIV infection. J Infect Dis.2000;181:946-953.
Mocroft A, Katlama C, Johnson AM.
et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet.2000;356:291-296.
d'Arminio Monforte A, Cozzi Lepri A, Rezza G.
et al. Insights into the reasons for discontinuation of the first highly active
antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve
Mocroft A, Youle M, Moore A.
et al. Reasons for modification and discontinuation of antiretrovirals: results
from a single treatment centre. AIDS.2001;15:185-194.
Deeks SG, Hecht FM, Swanson M.
et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in
an urban AIDS clinic: response to both initial and salvage therapy. AIDS.1999;13:F35-F43.
Raboud JM, Monatner JS, Conway B.
et al. Suppression of plasma viral load below 20 copies/mL is required to
achieve a long-term response to therapy. AIDS.1998;12:1619-1624.
Staszewski S, Morales-Ramirez J, Tashima KT.
et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir,
and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection
in adults. N Engl J Med.1999;341:1865-1873.
Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral
Avanti Study Group. Avanti 2: a randomized, double-blind trial to evaluate the efficacy
and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine
plus indinavir in HIV-infected antiretroviral naïve patients. AIDS.2000;14:367-374.
Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk
factors for virologic failure and adverse drug reactions. Ann Intern Med.1999;131:81-87.
Mocroft A, Gill MJ, Davidson W, Phillips AN. Predictors of a viral response and subsequent virological treatment
failure in patients with HIV starting a protease inhibitor. AIDS.1998;12:2161-2167.
Grabar S, Pradier C, Le Corfec E.
et al. Factors associated with clinical and virological failure in patients
receiving triple therapy including a protease inhibitor. AIDS.2000;14:141-149.
Casado JL, Perez-Elias MJ, Antela A.
et al. Predictors of long-term respones to protease inhibitor therapy in a
cohort of HIV-infected patients. AIDS.1998;12:F131-F135.
Miller V, Staszewski S, Sabin C.
et al. CD4 cell count as a predictor of the duration of highly active antiretroviral
therapy induced suppression of HIV virus load. J Infect Dis.1999;180:530-533.
Mocroft A, Devereux H, Kinloch-de-Loes S.
et al. Immunological, virological and clinical response to highly active antiretroviral
therapy treatment regimens in a complete clinic population. AIDS.2000;14:1545-1552.
Paredes R, Mocroft A, Kirk O.
et al. Predictors of virological success and ensuing failure among HIV positive
patients starting HAART in Europe: results from the EuroSIDA study. Arch Intern Med.2000;160:1123-1132.
Yerly S, Kaiser L, Perneger TV.
et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia:
the Swiss HIV Cohort Study. AIDS.2000;14:243-249.
Rizzardi GP, DeBoer RJ, Hoover S.
et al. Predicting the duration of antiretroviral treatment needed to suppress
plasma HIV-1 RNA. J Clin Invest.2000;105:777-782.
Cozzi Lepri A, Phillips AN, d'Arminio Monforte A.
et al. When to start highly active antiretroviral therapy in chronically HIV-infected
patients: evidence from the ICONA study. AIDS.2001;15:983-990.
Viard J, Mocroft A, Chiesi A.
et al. Influence of age on CD4 cell recovery in HIV-infected patients receiving
HAART: evidence from the EuroSIDA study. J Infect Dis.2001;183:1290-1294.
Bassetti S, Battegay M, Furrer H.
et al. Why is highly active antiretroviral therapy not prescribed or discontinued? J Acquir Immune Defic Syndr.1999;21:114-119.
Mellors JW, Munoz A, Giorgi JV.
et al. Plasma viral load and CD4+ lymphocytes as prognostic markers
of HIV-1 infection. Ann Intern Med.1997;126:946-954.
Touloumi G, Hatzakis A, Rosenberg PS, O'Brien TR, Goedert JJ. Effects of age at seroconversion and baseline HIV RNA level on the
loss of CD4+ cells among persons with hemophilia. AIDS.1998;12:1691-1697.